MarketPulse

NK cell therapy

2 articles
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for Anktiva

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.
IBRXbladder cancerAnktiva
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges 10% on NK Cell Therapy Manufacturing Milestone

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.
IBRXBBPclinical trialbladder cancer